Consumer News Popular Weight Loss Drugs Could Lower The Risk Of Certain Cancers, Study Finds
Search Related Content
Sorry, Your Requested Page Was Not Found. Greetings! We apologize for the inconvenience, but the page, Consumer News Popular Weight Loss Drugs Could Lower The Risk Of Certain Cancers, Study Finds is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3-18 months after their creation date. We prefer to keep content fresh and current, rather than holding onto outdated news. Thanks for visiting today.Search RobinsPost News & Noticias
GLP-1 weight-loss medications linked to improved cancer survival in certain patients
GLP-1 medications may help colon cancer patients live longer by reducing inflammation and improving metabolic health, UC San Diego researchers found in a 6,800-patient study. Read More
Eli Lilly weight-loss drug appears to suppress binge-eating signal, small study finds
Researchers monitoring the brain activity of a patient with a severe binge-eating problem reported that Eli Lilly's GLP-1 weight-loss drug appeared to temporarily suppress food-craving signals in the ... Read More
A New Study Found That Weight-Loss Drugs Like Ozempic Could Lower Your Heart Attack Risk
A new University College London study featuring 17,604 participants age 45 and up discovered that semaglutide -- a GLP-1 agonist found in weight-loss drugs like Ozempic and Wegovy -- decreases the ... Read More
Popular weight-loss drugs show added heart protection for diabetes patients
Injectable weight-loss drugs can reduce the risk of serious cardiovascular events for people with type 2 diabetes. Researchers at the Technical University of Munich (TUM) and Harvard Medical School ... Read More
White House Deal Lowers Prices of Weight-Loss Drugs
The White House announced reduced pricing for the popular weight-loss drugs made by Eli Lilly and Novo Nordisk. Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus